<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194775</url>
  </required_header>
  <id_info>
    <org_study_id>CS1003-305</org_study_id>
    <nct_id>NCT04194775</nct_id>
  </id_info>
  <brief_title>A Study of CS1003 in Subjects With Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CStone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CStone Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blind, randomized, phase III study to investigate the efficacy&#xD;
      and safety of CS1003 in combination with lenvatinib and placebo in combination with&#xD;
      lenvatinib in the treatment of subjects with no prior systemic treatment and with&#xD;
      unresectable advanced hepatocellular carcinoma (HCC). Subjects cannot be eligible for&#xD;
      locoregional therapy. In this study, CS1003 (or placebo) and lenvatinib are both considered&#xD;
      as the study treatment while CS1003 (or placebo) is the investigational product of and&#xD;
      lenvatinib is selected as the basic treatment for HCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 13, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) evaluated by the Blinded Independent Central Review Committee (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>up to approximately 42 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to approximately 42 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>CS1003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CS1003 placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1003+Lenvatinib</intervention_name>
    <description>CS1003, intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily</description>
    <arm_group_label>CS1003</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CS1003 Placebo+Lenvatinib</intervention_name>
    <description>CS1003 Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily</description>
    <arm_group_label>CS1003 placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. Age ≥18 years on the day of signing informed consent-(For Taiwan, the lower limit of&#xD;
             age is 20 years).&#xD;
&#xD;
          2. Subjects with unresectable advanced HCC, that is not eligible for surgery and/or&#xD;
             locoregional therapy (Stage B or C based on Barcelona Clinic Liver Cancer [BCLC]&#xD;
             staging system, and meets either one of the following criteria: 1) histologically or&#xD;
             cytologically confirmed diagnosis of HCC, 2) clinically confirmed diagnosis of HCC&#xD;
             according to American Association for the Study of Liver Diseases (AASLD) criteria.&#xD;
             Patients without cirrhosis require histological confirmation of diagnosis.&#xD;
&#xD;
          3. With at least one measurable lesion can be assessed&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.&#xD;
&#xD;
          5. Life expectancy ≥ 3 months.&#xD;
&#xD;
          6. Child-Pugh A&#xD;
&#xD;
          7. No prior systemic treatment for advanced HCC&#xD;
&#xD;
          8. Subjects with hepatitis B virus (HBV) infection, # are willing to continue receiving&#xD;
             antiviral treatment while on study.&#xD;
&#xD;
          9. Subjects have adequate organ and marrow function. Female subjects with childbearing&#xD;
             potential must have negative serum pregnancy test result at screening. Female subjects&#xD;
             with childbearing potential, and male subjects and their female partners with&#xD;
             childbearing potential must agree to use an contraceptive method(s) from the day of&#xD;
             signing informed consent form (ICF), during the study and till at least 6 months after&#xD;
             the last dose of study treatment.&#xD;
&#xD;
             Exclusion criteria&#xD;
&#xD;
         10. Fibrolamellar-HCC, sarcomatoid, cholangiocellular carcinoma or mixed&#xD;
             cholangiocarcinoma and HCC.&#xD;
&#xD;
         11. A prior bleeding event due to esophageal within 6 months or other gastrointestinal&#xD;
             bleeding events within 28 days prior to screening.&#xD;
&#xD;
         12. Malabsorption syndrome or inability to take oral medication due to other causes.&#xD;
&#xD;
         13. HBV and HCV co-infection.&#xD;
&#xD;
         14. Investigator evaluates to increase the drug related risk caused by enrolling subjects&#xD;
             in trial and taking study drug, or any serious or uncontrolled systematic disease that&#xD;
             confound the drug absorption or the study outcome, e,g diabetes mellitus,&#xD;
             hypertension, rheumatoid arthritis, major cardiovascular disease and so on.&#xD;
&#xD;
         15. Surgery or locoregional therapy for palliative purpose within 4 weeks prior to study&#xD;
             treatment.&#xD;
&#xD;
         16. History of other malignancy(ies) in the past 5 years, except for malignant disease&#xD;
             treated with curative intent and without active disease.&#xD;
&#xD;
         17. Known history of human immunodeficiency virus (HIV) infection or acquired&#xD;
             immunodeficiency syndrome (AIDS).&#xD;
&#xD;
         18. Current or prior use of systemic corticosteroid (&gt; 10 mg/day prednisone or equivalent)&#xD;
             or other immunosuppressive medication within 14 days prior to the first dose of study&#xD;
             treatment.&#xD;
&#xD;
         19. History of bone marrow transplantation or organ transplantation.&#xD;
&#xD;
         20. History of anaphylaxis or hypersensitivity to any ingredient of the investigational&#xD;
             product.&#xD;
&#xD;
         21. Any contraindication of lenvatinib.&#xD;
&#xD;
         22. Known history of drugs abuse that would interfere with cooperation with the&#xD;
             requirements of the trial.&#xD;
&#xD;
         23. Pregnant or lactating female subjects.&#xD;
&#xD;
         24. History of psychiatric disease that would interfere with cooperation with the&#xD;
             requirements of the trial; lack of or with restricted physical capability.&#xD;
&#xD;
         25. QTc interval &gt; 470 msec (as calculated with Fridericia's formula) at screening&#xD;
             electrocardiogram (ECG);&#xD;
&#xD;
         26. Any condition that would in the investigator's judgment, prevent the subject from&#xD;
             participating in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hua Hu, Master</last_name>
    <phone>+86 21 60333416</phone>
    <email>CStoneRA@cstonepharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California GI and Liver Centers</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassanein Tarek</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayali Zeid</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thuluvath Paul</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMass Memorial Health</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gultawatvichai Patan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Hospital</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sher Amna</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201203</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia Fan</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

